Literature DB >> 12117344

Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer.

Nigel J P Beasley1, John Lee, Spiro Eski, Paul Walfish, Ian Witterick, Jeremy L Freeman.   

Abstract

OBJECTIVES: To study the clinical and pathological variables predicting lymph node metastases in patients with well-differentiated thyroid carcinoma and to examine the impact of these metastases on recurrence and survival.
DESIGN: Cohort study. Median follow-up, 56 months.
SETTING: Tertiary referral university teaching hospital. PATIENTS: The study included 522 consecutive patients with well-differentiated thyroid carcinoma treated between 1964 and 1999. Data were collected on age, sex, family history of thyroid disease, prior radiation exposure, stage of disease, pathological diagnosis, size of tumor, multifocality of disease, recurrence, and survival. INTERVENTION: Total thyroidectomy and postoperative iodine 131 ablation. MAIN OUTCOME MEASURES: Disease-free and overall survival.
RESULTS: A total of 347 patients with stage I disease and 118 with stage II disease were identified. The median age of patients with neck disease was 3 years younger than those without neck disease and most had papillary carcinoma. Patients with multifocal disease were more likely to have neck disease (P =.02). On univariate analysis, disease-free and overall survival rates were significantly lower in patients who presented with neck node metastases (P<.001 and P =.005); this difference in survival remained highly significant on multivariate analysis for disease-free survival (P =.001), with a relative hazard of 6.27.
CONCLUSIONS: When treated with total thyroidectomy and routine postoperative iodine 131 ablation, patients with well-differentiated thyroid carcinoma who present with neck node metastases outside the central compartment of the neck have an approximately 6-fold risk of developing recurrences, most of which occur in the neck.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117344     DOI: 10.1001/archotol.128.7.825

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  30 in total

1.  S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging.

Authors:  Martin Nipp; Mareike Elsner; Benjamin Balluff; Stephan Meding; Hakan Sarioglu; Marius Ueffing; Sandra Rauser; Kristian Unger; Heinz Höfler; Axel Walch; Horst Zitzelsberger
Journal:  J Mol Med (Berl)       Date:  2011-09-22       Impact factor: 4.599

2.  Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone.

Authors:  Jong-Lyel Roh; Jae-Yong Park; Chan Il Park
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

3.  Level IIb lymph node metastasis in thyroid papillary carcinoma.

Authors:  Yusuf Vayisoglu; Cengiz Ozcan; Ozgur Turkmenoglu; Kemal Gorur; Murat Unal; Ahmet Dag; Koray Ocal
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-07       Impact factor: 2.503

4.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.

Authors:  Daniel Mankarios; Peter Baade; Pip Youl; Robin H Mortimer; Adedayo A Onitilo; Anthony Russell; Suhail A R Doi
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

5.  MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.

Authors:  Adriana Sondermann; Flavia Maziero Andreghetto; Ana Carolina Bernardini Moulatlet; Elivane da Silva Victor; Marilia Germanos de Castro; Fábio Daumas Nunes; Lenine Garcia Brandão; Patricia Severino
Journal:  Clin Exp Metastasis       Date:  2015-05-26       Impact factor: 5.150

6.  Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma.

Authors:  J-W Feng; X-H Yang; B-Q Wu; D-L Sun; Y Jiang; Z Qu
Journal:  Clin Transl Oncol       Date:  2019-03-16       Impact factor: 3.405

7.  A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis.

Authors:  Zhong Ying Rui; Yang Liu; Wei Zheng; Xuan Wang; Zhao Wei Meng; Jian Tan; Ning Li; Qiang Jia
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

8.  Role of prophylactic central neck dissection in cN0 papillary thyroid cancer.

Authors:  S Costa; G Giugliano; L Santoro; A Ywata De Carvalho; M A Massaro; B Gibelli; E De Fiori; E Grosso; M Ansarin; L Calabrese
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-04       Impact factor: 2.124

9.  Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation.

Authors:  Frederik A Verburg; Bart de Keizer; Marnix G E H Lam; J M H de Klerk; Cornelis J M Lips; Inne H M Borel-Rinkes; Johannes W van Isselt
Journal:  World J Surg       Date:  2007-12       Impact factor: 3.352

Review 10.  Involvement of level IIb lymph node metastasis and dissection in thyroid cancer.

Authors:  Yusuf Vayisoglu; Cengiz Ozcan
Journal:  Gland Surg       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.